louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07027644: The Synergistic Effects of Integrated Neuromuscular Inhibition Technique and Dry Cupping Therapy on Pain Modulation and Functional Recovery on Myofascial Trigger Points of Upper Trapezius
Official title: The Synergistic Effects of Integrated Neuromuscular Inhibition Technique and Dry Cupping Therapy on Pain Modulation and Functional Recovery on Myofascial Trigger Points of Upper Trapezius: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Mechanical Neck Pain
Keywords: Dry cupping
Integrated Neuromuscular Inhibition technique
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2025-06-18
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate the Synergistic Effects of the Integrated Neuromuscular Inhibition Technique and Dry Cupping Therapy on Pain Modulation and functional recovery on Myofascial Trigger Points of the upper trapezius


Eligibility criteria: Inclusion Criteria:

* Medically competent men and women will be included They had chronic MTrPs in the upper trapezius for more than 6 months Diagnostic criteria of being a tight band with a palpable nodule and distant pain when subjected to pressure

Exclusion Criteria:

* subjects with previous neck or shoulder pathology (e.g., fracture, sur¬gery, inflammatory and infectious diseases), cervical disc pathology, systemic disorder, fibromyalgia, those who underwent physical therapy for at least the previous 3 months

Primary outcomes:
measure: Pain intensity
timeFrame: 0-4 weeks
measure: pain pressure threshold
timeFrame: 0-4 weeks
Secondary outcomes:
measure: Neck Disability Index
timeFrame: 0-4 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00660244: Breast Cancer Tumor Care Observational Programme
Official title: Breast Cancer Tumor Care Patient Observation Programme
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Post Menopausal
Arthralgia
Keywords: Arimidex
Post menopausal
arthralgia
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-04-17
Enrollment: 150
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Postmenopausal women

Brief summary: The purpose of this study is to investigate efficacy and tolerability under anastrozole (Arimidex) treatment.


Eligibility criteria: Inclusion Criteria:

* Postmenopausal women
* Already on upfront Arimidex Therapy (Start 1-4 weeks before)
* HR+

Exclusion Criteria:

* Premenopausal women
* Tamoxifen switch patients

Primary outcomes:
measure: Progression of disease and tolerability in general
timeFrame: Baseline, every 3 month
Secondary outcomes:
measure: Patient questionnaire to collect data on Incidence, time of onset and treatment of arthralgia
timeFrame: Baseline, every 3 month
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Research Site
Study officials:
affiliation: Hospital Rudolfstiftung
name: Dr. Melichart
role: STUDY_CHAIR
affiliation: AKH-Vienna
name: Dr. Feistauer
role: STUDY_CHAIR
References:
Clinical trial NCT03820544: SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstructive Jaundice
Official title: Preoperative Endoscopic Biliary Drainage With Self Expanding Metal Stents (SEMS) vs. Direct Surgical Resection for Patients With Severe Obstructive Jaundice
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pancreatic Cancer
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2019-01-29
Enrollment: 4
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This trial studies the side effects of self expanding metal stent (SEMS) placement before surgery in unblocking the bile duct in patients with periampullary pancreatic cancer with severe obstructive jaundice. SEMS placement unblocks the bile duct and may help in improving bile drainage prior to surgery in patients with periampullary pancreatic cancer with severe obstructive jaundice.

Detailed description: PRIMARY OBJECTIVES:

I. To compare the 30-day overall complication rates between patients with severe obstructive jaundice undergoing preoperative endoscopic biliary drainage with self expanding metal stents (SEMS) and patients undergoing direct surgical resection.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of operable peri-ampullary pancreatic cancer as determined by the Department of Surgery per their standard of care
* Serum bilirubin \> 10 mg/dl
* Adequate birth control

Exclusion Criteria:

* Patients with evidence of distant metastasis on computed tomography (CT) or magnetic resonance imaging (MRI)
* Patients anticipated to require vascular reconstruction
* Patients with cholangitis
* Patients for whom surgery is deemed inappropriate by surgeon
* Patients with bilirubin less than 10 mg/dL or greater than 20 mg/dL
* Patients who previously underwent biliary decompression for cholangitis by ERCP or percutaneous transhepatic cholangiography (PTC)
* Patients with low performance score (Karnofsky performance status scale \< 50)
* Patients with known preexisting liver disease with associated elevated bilirubin
* Patients who are pregnant or actively breast feeding

Primary outcomes:
measure: Complication Rates of Grade III or Higher
timeFrame: At 30 days post-surgery
measure: Intraoperative Estimated Blood Loss
timeFrame: At time of surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Sidney Kimmel Cancer Center at Thomas Jefferson University
state: Pennsylvania
Study officials:
affiliation: Sidney Kimmel Cancer Center at Thomas Jefferson University
name: Thomas Kowalski, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00408044: Dysesthesia Study After Sternotomy
Official title: Pain After Sternotomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ischemic Cardiopathy
Other Forms of Cardiopathy
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2006-12-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: Chronic pain associated to sternotomy occurs in 40 to 50% of patients after cardiac surgery.

33 to 66% of these patients suffer during 3 month and 25 to 33% have postoperative pain for at least 1 year.

This pain has often negative effects on daily activity. Despite its frequency and importance, the etiology of this chronic pain is not completely understood.

The goal of this study is to understand the mechanism of this chronic pain, to prevent and/or to treat better in the future.

The sensitivity of the thorax after cardiac surgery seems to follow a dynamic evolution which can be observed within several weeks. Therefore we decided to study this evolution.

This study is different from previous ones observing the sensitivity of the thorax at a well defined moment immediately after the surgery.


Eligibility criteria: Inclusion Criteria:

* Cardiac surgery with sternotomy

Exclusion Criteria:

* patients with chronic pain
* redo surgery
* patients with neurological pathologies
* patients treated with antidepressant medication

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint Luc
Study officials:
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Mona Momeni, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02624544: Proton Pump Inhibitors Use in Patients With Psoriasis
Official title: Proton Pump Inhibitors Use in Patients With Psoriasis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Psoriasis
Lead sponsor: EMS
Sponsor class: INDUSTRY
First posted: 2015-12-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Detailed description: Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

The study will assess the evolution of skin lesions in psoriasis patients using PPIs

Eligibility criteria: Inclusion Criteria:

* Diagnostic of Psoriasis

Exclusion Criteria:

* Pregnancy

Primary outcomes:
measure: Efficacy - Change from baseline in skin lesions at 5 months
timeFrame: Baseline - 5 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Rahman M, Alam K, Ahmad MZ, Gupta G, Afzal M, Akhter S, Kazmi I, Jyoti, Ahmad FJ, Anwar F. Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):287-302. doi: 10.2174/187153012802002901.
Clinical trial NCT02485444: Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion
Official title: Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage Management After Second-trimester Abortion: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Abortion, Induced
Labor Stage, Third/Drug Effects
Pregnancy Trimester, Second
Oxytocin/Administration & Dosage
Lead sponsor: Ataturk University
Sponsor class: OTHER
First posted: 2015-06-30
Enrollment: 160
Sex: FEMALE
Minimum age (years): 17
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares oxytocin infusion to spontaneous follow-up for third-stage of labor at induced mid-trimester abortions. Patients will be randomized to oxytocin infusion or observation with no pharmacologic intervention. Primary outcome of the study is complete abortion rate within two hours of fetal delivery.


Eligibility criteria: Inclusion Criteria:

-Women who had mid-trimester termination of pregnancy between 13-24 gestational weeks

Exclusion Criteria:

* If fetus and placenta expelled together
* Obstetrical haemorrhage needs intervention
* Known prostaglandin allergy

Primary outcomes:
measure: Complete abortion rate
timeFrame: within 5 minute after placenta delivered
Secondary outcomes:
measure: Blood loss estimated by gravimetric method
timeFrame: within 10 minutes after delivery of placenta
measure: Transfusion rate
timeFrame: Within 7 days of hospitalization
measure: Change in hemoglobin measured by difference in hemoglobin before and 24-hour after abortion
timeFrame: 24 hours after delivery of placenta
measure: Placenta delivery time measured by time elapsed until the delivery of the placenta from the delivery of foetus
timeFrame: 5 minute after delivery of placenta
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Atatürk Üniversitesi Araştırma Hastanesi
Study officials:
affiliation: Ataturk University
name: Omer E Yapca, MD
role: STUDY_CHAIR
affiliation: Ataturk University
name: Ragıp A AL, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00636844: Detection of Chemotherapy Induced Cardiotoxicity
Official title: Detection of Chemotherapy Induced Cardiotoxicity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Keywords: chemotherapy, cardiotoxicity
Lead sponsor: George Washington University
Sponsor class: OTHER
First posted: 2008-03-17
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Oncology clinic patients

Brief summary: To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).

Detailed description: To identify patients at risk of development of heart damage after receiving chemotherapy by obtaining the genetic profile of those who show: elevation of troponin, left ventricular systolic and diastolic dysfunction, and pro-oxidant stress markers.

Eligibility criteria: Inclusion Criteria:

* undergoing anthracycline and/or trastuzumab therapy for the first time

Exclusion Criteria:

* abnormal ventricular ejection fraction
* past history of, or active cardiac disease including: MI, CHF, angina, arrhythmia requiring medication, valvular disease, uncontrolled systemic hypertension

Primary outcomes:
measure: The genetic profile of patients with anthracycline-induced elevation of troponin-I
timeFrame: one year
Secondary outcomes:
measure: Assess the genetic profile of patient with anthracycline-induced left ventricular systolic and diastolic dysfunction
timeFrame: one year
measure: Assess the relationship of quantitative increases of pro-oxidant stress and a specific genetic profile
timeFrame: one year
Other outcomes:
Locations:
city: Washington
country: United States
facility: George Washington University
state: District of Columbia
Study officials:
affiliation: George Washington University
name: Jannet Lewis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00929344: Duloxetine Versus Pregabalin for Alcohol Dependence
Official title: Duloxetine Versus Pregabalin for Alcohol Dependence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alcohol Dependence
Keywords: Alcohol
Alcohol treatment
Alcoholism
Alcohol Abuse
Alcohol Dependence
Lead sponsor: The Scripps Research Institute
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2009-06-29
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A 12-week, double-blind, placebo-controlled parallel group study will be conducted with 150 outpatients with alcohol dependence, with random assignment to pregabalin 300 mg/d, duloxetine 40 mg/d, or placebo in conjunction with manual-guided behavioral counseling and follow-up visits 1 week and 3 months post-treatment.


Eligibility criteria: Inclusion Criteria:

* Males or females 18 years of age
* Meets DSM-IV criteria for current alcohol dependence and drinking an average of ≥21 drinks weekly for males, ≥14 females,
* Seeking research-based outpatient treatment for alcohol problems
* Willing to attend 12 weekly study visits and 2 follow-up visits
* Have normal bilirubin, and ALT, AST, and GGT values no more than 3x the ULN, and no evidence of hepatic insufficiency

Exclusion Criteria:

* Active suicidal ideation
* Medical disorders that will increase potential risk or interfere with study participation
* Sexually active female subjects with childbearing potential who are pregnant, nursing or refuse to use a reliable method of birth control
* Males who refuse to use a reliable method of birth control
* Meets DSM-IV criteria for any other current major AXIS I disorder other than alcohol or nicotine dependence.
* Inability to understand and/or comply with the provisions of the protocol and consent form
* Treatment with an antidepressant medication during the two weeks, or fluoxetine during the month, prior to randomization
* Ongoing treatment with disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral) or other medications that may affect study outcomes, e.g., anticonvulsants or other drugs that act on serotonin in the brain
* Ongoing treatment with drugs that may increase potential risk (Actos),

Primary outcomes:
measure: Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Week at Week 12
timeFrame: Baseline and Week 12
measure: Change From Baseline in Drinking Quantity and Frequency Using Drinking Days Per Week at Week 12
timeFrame: Baseline and Week 12
measure: Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Drinking Day at Week 12
timeFrame: Baseline and Week 12
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research
state: California
Study officials:
affiliation: The Scripps Research Institute
name: Barbara J Mason, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03590444: Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser
Official title: Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetic Retinal Edema
Lead sponsor: Hospital Hietzing
Sponsor class: OTHER
First posted: 2018-07-18
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics.

Detailed description: Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics.

Prospective clinical trial (50 treatment-naive eyes) with DME randomized 1:1 receiving intravitreal ranibizumab (0.5 mg/0.05 ml) and prompt grid laser compared to ranibizumab and deferred laser. Morphological characteristics potentially relevant for prognosis were assessed at baseline, month 6, month 9, year 1, 2, 3, 4 and 5 of follow-up.

Grid laser and ranibizumab therapy is expected to be effective in DME management during long-term follow-up. Immediate combined therapy will likely signify a trend of functional superiority in an early disease phase. Intraretinal hyperreflective material in SD-OCT will likely negatively related to BCVA.

Eligibility criteria: Inclusion criteria:

* DME that will be detected clinically and on FA as well as on SD-OCT \[diffuse macular edema with central retinal thickness (CRT) ≥300µm involving the center of the macular area\]
* Patients will be included into the present study following informed consent
* Best-corrected-visual-acuity (BCVA) between 0.06 (1.2logMAR) and 0.63 (0.20logMAR).

Exclusion criteria:

* Eyes with other retinal diseases \[i.e. age-related macular degeneration (AMD) and associated choroidal neovascularization (CNV), cystoid macular edema (CME) of other origin (e.g. uveitis, Irvine-Gass syndrome, retinal vein occlusion), or retinal dystrophies\]

Primary outcomes:
measure: Visual acuity
timeFrame: 1 year
Secondary outcomes:
measure: Additional morphological characteristics in spectral Domain SD-OCT
timeFrame: 1 year
measure: Central retinal thickness
timeFrame: 1 year
Other outcomes:
Locations:
city: VIenna
country: Austria
facility: Hietzing Hospital
Study officials:
affiliation: Hietzing Hospital Vienna, Austria
name: Christopher Schütze, Ass.Prof. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01052844: Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy
Official title: Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vomiting
Cisplatin Adverse Reaction
Keywords: Vomiting
Antiemetics
Dexamethasone
Cisplatin
Antineoplastic combined chemotherapy protocols
Lead sponsor: Faculdade de Medicina do ABC
Sponsor class: OTHER
First posted: 2010-01-20
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Gabapentin is an antiepileptic drug. Its antiemetic effect is demonstrated after laparoscopic surgery, but it is not yet known whether gabapentin is effective in preventing chemotherapy induced emesis.

The purpose of this study is to determine whether the addition of gabapentin to dexamethasone plus ondansetron increase the control of chemotherapy-induced nausea and vomiting.

Detailed description: This was a prospective, double-blind, placebo-controlled study conducted at our institution (Faculdade de Medicina da Fundação ABC and affiliated Hospitals) from April 2009 to April 2010. Patients and personnel involved in the study were blinded to the assigned treatment. The study was approved by the ethics committee of our institution. All the patients provided written informed consent.

Eligibility criteria: Inclusion Criteria:

* First course of chemotherapy ( cisplatin or doxorubicin at a dose of at least 50mg per square meter)
* Written informed consent must be obtained before initiating the protocol procedures

Exclusion Criteria:

* ECOG 3
* Nausea and vomiting within the past 1 day
* Gastrointestinal obstruction
* Concurrent use of opioid
* Patients with brain metastases
* History of allergic or other adverse reaction to gabapentin

Primary outcomes:
measure: Number of Patients With Complete Response During Chemotherapy Course 1
timeFrame: 5 days
measure: Number of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1
timeFrame: 6 days
Secondary outcomes:
Other outcomes:
Locations:
city: Santo André
country: Brazil
facility: Faculdade de Medicina do ABC
state: São Paulo
Study officials:
affiliation: Faculdade de Medicina do ABC
name: Auro del Giglio, phD
role: STUDY_DIRECTOR
References:
citation: Cruz FM, de Iracema Gomes Cubero D, Taranto P, Lerner T, Lera AT, da Costa Miranda M, da Cunha Vieira M, de Souza Fede AB, Schindler F, Carrasco MM, de Afonseca SO, Pinczowski H, del Giglio A. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer. 2012 Mar;20(3):601-6. doi: 10.1007/s00520-011-1138-4. Epub 2011 Apr 5.